Key Points
- Benjamin Landry sold 27,425 shares of Health Catalyst at $2.64 each for $72,402, reducing his stake by 21.52% to 100,000 shares following the transaction disclosed in an SEC filing.
- Health Catalyst shares trade near multi‑year lows with a market cap of about $185 million; the company posted a slight quarterly EPS beat but has negative margins and a consensus analyst rating of Hold with an average target of $4.36.
Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 27,425 shares of the firm's stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $2.64, for a total transaction of $72,402.00. Following the completion of the sale, the general counsel owned 100,000 shares of the company's stock, valued at $264,000. The trade was a 21.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Health Catalyst Trading Down 1.1%
HCAT stock opened at $2.61 on Wednesday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. Health Catalyst, Inc. has a twelve month low of $2.02 and a twelve month high of $8.52. The company has a market cap of $184.61 million, a P/E ratio of -1.64 and a beta of 1.72. The business has a fifty day moving average of $2.83 and a 200-day moving average of $3.29.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.01. The business had revenue of $76.32 million for the quarter, compared to analysts' expectations of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. As a group, equities research analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current year.
Institutional Investors Weigh In On Health Catalyst
A number of hedge funds and other institutional investors have recently bought and sold shares of HCAT. Numerai GP LLC acquired a new position in Health Catalyst during the 3rd quarter worth approximately $351,000. Millennium Management LLC boosted its position in Health Catalyst by 2,513.3% during the third quarter. Millennium Management LLC now owns 1,589,536 shares of the company's stock valued at $4,530,000 after purchasing an additional 1,528,710 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Health Catalyst in the third quarter valued at approximately $90,000. Moore Capital Management LP raised its stake in shares of Health Catalyst by 130.8% during the 3rd quarter. Moore Capital Management LP now owns 398,857 shares of the company's stock worth $1,137,000 after purchasing an additional 226,023 shares in the last quarter. Finally, First Light Asset Management LLC boosted its holdings in shares of Health Catalyst by 9.9% in the 3rd quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company's stock valued at $38,293,000 after buying an additional 1,206,039 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have commented on HCAT shares. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $9.00 to $5.00 and set a "buy" rating for the company in a report on Friday, August 29th. Citigroup cut their target price on Health Catalyst from $3.50 to $3.25 and set a "neutral" rating on the stock in a research note on Tuesday, November 11th. Piper Sandler cut Health Catalyst from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $8.00 to $4.00 in a research note on Wednesday, August 27th. Weiss Ratings reissued a "sell (e+)" rating on shares of Health Catalyst in a research report on Monday. Finally, Stifel Nicolaus reduced their target price on Health Catalyst from $4.50 to $3.75 and set a "hold" rating on the stock in a report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $4.36.
Get Our Latest Stock Analysis on HCAT
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
